Medscape Conference Coverage, based on selected sessions at the:

European Society of Cardiology (ESC) 2008 Congress

August 30 - September 03, 2008; Munich, Germany

This activity is not sanctioned by, nor a part of, the European Society of Cardiology. Conference news does not receive grant support and is produced independently.

Featured Coverage

Conference News

  • UK Indians with ACS present younger

    A new prospective British study has found that Indian Asians with acute coronary syndrome presenting to a chest pain clinic were, on average, almost 10 years younger than white Europeans presenting for the same reason, and they also had a much higher incidence of triple-vessel disease.
    Medscape Medical News, September 19, 2008
  • Early Enzyme Treatment Best in Fabry's Disease

    A new study has found that in patients with Fabry's disease, the extent of myocardial fibrosis at baseline is crucial in determining how well they will respond to enzyme-replacement therapy.
    Heartwire, September 17, 2008
  • France Doing Well Too

    Three small countries--Luxembourg, Norway, and Switzerland--have emerged as the top nations for cardiac care in Europe in a new report. France comes a close fourth, scoring high on prevention.
    Heartwire, September 12, 2008
  • HORIZONS-AMI: Mortality and Major Bleeds

    Fewer major bleeding complications with bivalirudin accounted for the drug's observed significant clinical advantage over conventional heparin plus a glycoprotein IIb/IIIa inhibitor, according to its investigators.
    Heartwire, September 12, 2008
  • Natriuretic Peptide Marker and Acute HF

    It's a resurgence for atrial natriuretic peptide, the first in this class of hormones to be discovered. A fragment of its precursor molecule may have a future as a diagnostic marker.
    Heartwire, September 10, 2008
  • REVERSE at 18 Months

    The trial's extended follow-up of its European patients strengthens its earlier evidence that CRT can reverse cardiac remodeling even in NYHA class 1-2, and its suggestions of a clinical benefit continue to inspire optimism.
    Heartwire, September 8, 2008
  • Apixaban in Phase 2 Study

    The addition of apixaban to antiplatelet therapy resulted in an increase in bleeding, but there was also an observed trend toward a reduction in clinically relevant ischemic events, a new dose-ranging study has shown.
    Heartwire, September 5, 2008

    Investigators told the audience that almost 85% of patients wanted to know their risk of heart disease, but very few knew their real risk, assuming they were as healthy as men and women their own age. Also, more than 80% of those participating in the survey were not provided with a professional lifestyle and risk-factor management program, despite evidence that such programs are effective.
    Heartwire, September 3, 2008
  • Immunosuppression and Virus-Negative Inflammatory Cardiomyopathy

    The findings support a strategy of first testing patients for persistent viral load before choosing a treatment strategy.
    Heartwire, September 3, 2008
  • Tirofiban Cuts Periprocedural MI

    A new study in low-risk, elective-PCI patients who were also nonresponsive to aspirin and/or clopidogrel shows that adding tirofiban during PCI can cut MI rates by more than 40%, as compared with patients given a placebo infusion.
    Heartwire, September 3, 2008
  • FX06 of Little Benefit

    An exploratory phase 2 trial of a new small peptide compound, FX06, designed to cut reperfusion injury in STEMI patients, has failed to show a benefit on the primary end point. But the investigators are still planning a larger trial, convinced that the agent holds promise.
    Heartwire, September 2, 2008
  • Restenosis Rates for Endeavor Stent: SCAAR

    Investigators say the findings support calls for larger randomized trials comparing different DES, although whether the higher restenosis rates also affect mortality remains unclear.
    Heartwire, September 2, 2008
  • Vytorin Data in Aortic Stenosis Patients

    The SEAS data were presented today at the European Society of Cardiology, but the focus turned to the cancer risks observed in the trial. An analysis of ongoing studies--IMPROVE-IT and SHARP--suggests the finding is a play of chance, but others, including prominent New England Journal of Medicine editorialists, say there is uncertainty about the safety and efficacy of the drug.
    Heartwire, September 2, 2008
  • TRITON-TIMI 38: Clinical Gains for Prasugrel

    Diabetics with ACS treated with PCI who received the newer agent didn't show the increased bleeding risk observed in the overall trial.
    Heartwire, September 2, 2008
  • Better Survival With PCI in Stable CAD?

    The authors acknowledge that their analysis, which included COURAGE patients, will stoke new debate, but argue that their approach has endeavored to avoid selection bias while including the longest possible follow-up, something that has masked PCI's survival benefits in other studies.
    Heartwire, September 2, 2008
  • SYNTAX: DES Fail to Match CABG for Complex CAD

    While DES results failed to meet the test of noninferiority to CABG for a composite end point of death, MI, stroke, and revascularization, the two strategies had comparable rates of "hard" clinical events at one year. Rates of stroke were higher for CABG, while repeat procedures were more common for PCI.
    Heartwire, September 1, 2008
  • LEADERS at the ESC

    The novel stent platform, which elutes a sirolimus analog from a biodegradable platform, was noninferior to the sirolimus-eluting stent in terms of the primary end point of cardiac death, MI, and target-vessel revascularization.
    Heartwire, September 1, 2008
  • BEAUTIFUL: Negative Trial With Niche Benefits

    Ivabradine was no better than placebo in terms of reducing cardiac death and other coronary and heart-failure outcomes in the overall trial population; however, patients with heart rates higher than 70 bpm had reduced hospitalizations for heart failure and MI and reduced revascularizations with ivabradine.
    Heartwire, August 31, 2008
  • TRANSCEND Disappoints

    The angiotensin-receptor blocker telmisartan has fared no better than placebo in TRANSCEND in patients at high-risk of cardiovascular disease unable to tolerate ACE inhibitors, seemingly providing more questions than answers.
    Heartwire, August 31, 2008
  • TIME-CHF and HF Natriuretic-Peptide Targets

    Medical therapy aimed at cutting natriuretic-peptide levels to prespecified targets didn't improve hospitalization-free survival compared with symptom-guided management, but there were secondary suggestions that the novel management strategy might be helpful in patients younger than 75 years.
    Heartwire, August 31, 2008

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the European Society of Cardiology. These materials and the related activity are not sanctioned by the European Society of Cardiology or the commercial supporter of the conference and do not constitute an official part of that conference.